Spirix 25 mg Norge - norsk - Statens legemiddelverk

spirix 25 mg

orifarm healthcare a/s - spironolakton - tablett - 25 mg

Spirix 50 mg Norge - norsk - Statens legemiddelverk

spirix 50 mg

orifarm healthcare a/s - spironolakton - tablett - 50 mg

Spirix 100 mg Norge - norsk - Statens legemiddelverk

spirix 100 mg

orifarm healthcare a/s - spironolakton - tablett - 100 mg

TechneScan DTPA - Norge - norsk - Statens legemiddelverk

technescan dtpa -

curium netherlands b.v. - kalsiumtrinatriumpentetat - preparasjonssett til radioaktive legemidler

Ultra TechneKow FM - Norge - norsk - Statens legemiddelverk

ultra technekow fm -

curium netherlands b.v. - natriummolybdat mo-99 omdannet til natriumperteknetat tc-99m - radionuklidegenerator

Vectatone 1 % Norge - norsk - Statens legemiddelverk

vectatone 1 %

perrigo sverige ab - penciklovir - krem - 1 %

Vectavir 1 % Norge - norsk - Statens legemiddelverk

vectavir 1 %

perrigo sverige ab (1) - penciklovir - krem - 1 %

Yesafili Den europeiske union - norsk - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Øyemidler - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Cabometyx Den europeiske union - norsk - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Clopidogrel Acino Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.